What's behind Moderna's latest 3.5% stock surge?

Traders Union
All News
Stocks
Moderna rises 3.5% today to $206.01

Highlights

Moderna reported Phase 3 data for its melanoma vaccine with Merck showing a reduction in recurrence and metastasis, targeting FDA approval in 2027.
Regulatory scrutiny increased over Moderna's data disclosure practices related to the recent melanoma trial results leak.
Shares of Moderna are trading near session highs with mixed short-term indicators and an expected price range of $169.4 to $242.62 for the coming week.

Regulatory scrutiny rises after data leak despite FDA approval plans

Moderna recently faced notable volatility following the leak and subsequent presentation of Phase 3 data for its mRNA-based melanoma vaccine, intismeran, developed with Merck. The trial data demonstrated a meaningful reduction in recurrence and metastasis for melanoma patients treated with the vaccine in combination with KEYTRUDA, and the company confirmed plans to pursue FDA approval in 2027. Regulatory scrutiny increased around Moderna’s disclosure practices related to the data leak, and the company continues to invest in its mRNA therapeutics pipeline.

Anton Kharitonov, expert at Traders Union, highlights that Moderna's rally remains technically fragile. He points to the price stalling below the key 20-day moving average, with heavy intraday selling pressure and momentum signals flashing caution. The recent data leak and regulatory scrutiny cast doubts on sentiment, further weakening the bullish case. Kharitonov notes the risk of downside if support at $200.3 fails, as forecast bands suggest notable two-way risk. "With sentiment undermined by both technical and disclosure issues, I see limited appetite for sustained upside until resistance is convincingly broken," he says.

Viktoras Karapetjanc, expert at Traders Union, sees meaningful opportunity for Moderna following compelling Phase 3 trial results with intismeran. He believes the company’s plan to seek FDA approval signals strong fundamental progress. Karapetjanc views the medium- and long-term technical structure as bullish, with prices holding above key averages and upside targets in play. "The bullish structure remains intact here — further growth is expected as the market digests clinical milestones and regulatory actions," he states.

Sholanke Dele, market strategist, underscores widespread caution in the market despite positive clinical news. He notes that mixed technical momentum and regulatory concerns have weighed on sentiment. Dele remains skeptical about near-term gains as sellers dictate the intraday tone. "The news flow may excite, but I see persistent skepticism keeping upside limited for now," he comments.

Overhead resistance persists as sellers dominate intraday momentum

Moderna is trading below its 20-day moving average at $209.95, yet remains above both its 50-day and 200-day moving averages at $173.64 and $82.93. This technical alignment suggests immediate resistance overhead but maintains a bullish bias over the medium and long term, with the next near-term resistance at $207.08 and support established at the session's $200.3 high. MACD indicates strong buy momentum, but ADX, RSI, and CCI forecast selling pressure, and Bull/Bear Power is deeply negative at -8.59, highlighting intraday dominance by sellers amid an oversold condition. Stochastic RSI at 0 also indicates oversold levels. The stock opened with a downside gap but has recovered to session highs, though momentum signals remain mixed, and sellers maintain influence for now.

Previously it was reported that analysts saw Moderna at a critical technical crossroads after the release of its Phase 3 neoantigen therapy trial results in partnership with Merck. The latest confirmation of significant clinical benefit, combined with ongoing volatility and mixed momentum signals, shifts attention to whether the stock can decisively clear the $207.08 resistance, which could expose a wider upside trading band in the coming sessions.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.